Literature DB >> 20929608

The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression.

William R Lumry1, Anthony J Castaldo, Margaret K Vernon, Marc B Blaustein, David A Wilson, Patrick T Horn.   

Abstract

Hereditary angioedema (HAE) is a rare, autosomal dominant disorder characterized by recurrent acute attacks of swelling of the larynx, abdomen, and periphery. This study was designed to assess the humanistic burden of illness associated with HAE. HAE burden was assessed via a web-based survey of patients that solicited information on attack characterization, treatment, side effects, pain, and functional and emotional burden of disease management. In addition to HAE-specific sections, the survey used three standardized instruments to compare HAE patient data to normative (healthy) and chronic disease populations: the 12-Item Short Form (SF-12) Health Survey, the Work Productivity and Activity Impairment-General Health (WPAI-GH) questionnaire, and the Hamilton Depression Inventory-Short Form (HDI-SF). A total of 457 HAE patients responded to the survey (response rate, ∼19%). Patients reported significantly poorer health-related quality of life versus population norms, based on the SF-12 Physical Component Summary (mean, 43.7 versus 49.6; p < 0.001) and Mental Component Summary (mean, 42.6 versus 49.4; p < 0.001). HAE patients also had higher mean HDI-SF scores than population norms (8.1 ± 6.5 versus 3.1 ± 3.0; p < 0.001), with 42.5% of HAE patients scoring >8.5, indicative of depressive symptomatology. Productivity was also markedly impaired in all WPAI-GH categories, including 34% overall work impairment. Because of their most recent HAE attack, workers lost a mean of 3.3 days; students lost a mean of 1.9 days. HAE results in considerable humanistic burden to patients across physical and mental health domains; negatively impacts education, career, and work productivity; and compounds the substantial economic burdens that are reported separately.

Entities:  

Mesh:

Year:  2010        PMID: 20929608     DOI: 10.2500/aap.2010.31.3394

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  72 in total

Review 1.  New therapeutics in C1INH deficiency: a review of recent studies and advances.

Authors:  Neil Parikh; Marc A Riedl
Journal:  Curr Allergy Asthma Rep       Date:  2011-08       Impact factor: 4.806

2.  Current state of hereditary angioedema management: a patient survey.

Authors:  Aleena Banerji; Paula Busse; Sandra C Christiansen; Henry Li; William Lumry; Mark Davis-Lorton; Jonathan A Bernstein; Michael Frank; Anthony Castaldo; Janet F Long; Bruce L Zuraw; Marc Riedl
Journal:  Allergy Asthma Proc       Date:  2015 May-Jun       Impact factor: 2.587

3.  Management of hereditary angioedema in 2012: scientific and pharmacoeconomic perspectives.

Authors:  Stephen A Tilles; Larry Borish; Joshua P Cohen
Journal:  Ann Allergy Asthma Immunol       Date:  2012-12-17       Impact factor: 6.347

4.  Preventing Hereditary Angioedema Attacks in Children Using Cinryze®: Interim Efficacy and Safety Phase 3 Findings.

Authors:  Emel Aygören-Pürsün; Daniel Soteres; Dumitru Moldovan; Jim Christensen; Arthur Van Leerberghe; James Hao; Jennifer Schranz; Kraig W Jacobson; Inmaculada Martinez-Saguer
Journal:  Int Arch Allergy Immunol       Date:  2017-06-30       Impact factor: 2.749

Review 5.  Life with a Primary Immune Deficiency: a Systematic Synthesis of the Literature and Proposed Research Agenda.

Authors:  Morgan N Similuk; Angela Wang; Michael J Lenardo; Lori H Erby
Journal:  J Clin Immunol       Date:  2016-02-12       Impact factor: 8.317

6.  Successful treatment of acute hereditary angioedema attacks with self-administered icatibant in patients with venous access problems.

Authors:  Michaela Wiednig
Journal:  BMJ Case Rep       Date:  2013-04-25

7.  Content validity of visual analog scales to assess symptom severity of acute angioedema attacks in adults with hereditary angioedema: an interview study.

Authors:  Carolyn Vivienne McMillan; Jane Speight; Anurag Relan; Luca Bellizzi; Gerald Haase; Marco Cicardi
Journal:  Patient       Date:  2012       Impact factor: 3.883

8.  Depression and anxiety in patients with hereditary angioedema.

Authors:  Andrew S Fouche; Erika F H Saunders; Timothy Craig
Journal:  Ann Allergy Asthma Immunol       Date:  2013-06-25       Impact factor: 6.347

9.  Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trial.

Authors:  A Malbrán; M Riedl; B Ritchie; W B Smith; W Yang; A Banerji; J Hébert; G J Gleich; D Hurewitz; K W Jacobson; J A Bernstein; D A Khan; C H Kirkpatrick; D Resnick; H Li; D S Fernández Romero; W Lumry
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

Review 10.  Angioedema Phenotypes: Disease Expression and Classification.

Authors:  Maddalena Alessandra Wu; Francesca Perego; Andrea Zanichelli; Marco Cicardi
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.